Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorNombela, Paz
dc.contributor.authorLozano, Rebeca
dc.contributor.authorAytes, Alvaro
dc.contributor.authorMateo Valderrama, Joaquim
dc.contributor.authorOlmos, David
dc.contributor.authorCastro, Elena
dc.date.accessioned2019-05-20T07:44:44Z
dc.date.available2019-05-20T07:44:44Z
dc.date.issued2019-03-12
dc.identifier.citationNombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E, et al. BRCA2 and Other DDR Genes in Prostate Cancer. Cancers (Basel). 2019;11(3):e352.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11351/4072
dc.descriptionBRCA2; DDR; Prostate cancer
dc.description.abstractGermline and somatic aberrations in DNA damage repair (DDR) genes are more prevalent in prostate cancer than previously recognized, with BRCA2 as the most commonly altered gene. Germline mutations in BRCA2 have been linked to poor prognosis when patients are managed under the protocols currently approved for prostate cancer. The impact of germline mutations in other DDR genes beyond BRCA2 remain unclear. Importantly, a quarter of prostate cancer patients identified as germline mutation carriers lack a family history of cancer. The clinical implications of somatic DDR defects are yet to be elucidated. Poly ADP-ribose polymerase (PARP) inhibitors and platinum-based chemotherapy have proven to be effective in the treatment of other tumor types linked to BRCA1 and BRCA2 alterations and several trials are currently evaluating their efficacy in prostate cancer. Here, we summarize the available evidence regarding the prevalence of somatic and germline DDR defects in prostate cancer; their association with clinical outcomes; the trials assessing the efficacy of new therapies that exploit DDR defects in prostate cancer and briefly discuss some uncertainties about the most appropriate management for these patients.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;11(3)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPròstata - Càncer- Aspectes genètics
dc.subjectADN - Dany
dc.subjectADN - Reparació
dc.subject.meshProstatic Neoplasms
dc.subject.meshBRCA2 Protein
dc.subject.meshDNA Damage
dc.subject.meshDNA Repair
dc.subject.mesh/genetics
dc.titleBRCA2 and Other DDR Genes in Prostate Cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers11030352
dc.subject.decsneoplasias de la próstata
dc.subject.decsproteína BRCA2
dc.subject.decsdaño del ADN
dc.subject.decsreparación del ADN
dc.subject.decs/genética
dc.relation.publishversionhttps://www.mdpi.com/2072-6694/11/3/352
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Nombela P] Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Center, Madrid, Spain. [Lozano R, Olmos D] Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Center, Madrid, Spain. CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain. [Aytes A] Programs of Molecular Mechanisms and Experimental Therapeutics in Oncology (ONCOBell), and Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Spain. [Mateo J] Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Castro] Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Center, Madrid, Spain. Medical Oncology Department, Hospital Universitario Quironsalud Madrid, Madrid, Spain.
dc.identifier.pmid30871108
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record